News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
235,167 Results
Type
Article (5127)
Company Profile (25)
Press Release (230015)
Multimedia
Podcasts (3)
Webinars (4)
Section
Business (82274)
Career Advice (463)
Deals (15059)
Drug Delivery (9)
Drug Development (19095)
Employer Resources (30)
FDA (3686)
Job Trends (3926)
News (120231)
Policy (7514)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (302)
Accelerated approval (10)
Adcomms (4)
Allergies (20)
Alliances (14809)
ALS (52)
Alzheimer's disease (327)
Antibody-drug conjugate (ADC) (71)
Approvals (3828)
Artificial intelligence (129)
Autoimmune disease (61)
Automation (10)
Bankruptcy (97)
Best Places to Work (2873)
Biosimilars (38)
Biotechnology (23)
Bladder cancer (43)
Brain cancer (15)
Breast cancer (125)
Cancer (1111)
Cardiovascular disease (80)
Career advice (396)
Career pathing (4)
CAR-T (75)
CDC (3)
Celiac Disease (1)
Cell therapy (194)
Cervical cancer (8)
Clinical research (17015)
Collaboration (456)
Compensation (449)
Complete response letters (12)
COVID-19 (315)
CRISPR (17)
C-suite (468)
Cystic fibrosis (28)
Data (1763)
Denatured (2)
Depression (26)
Dermatology (21)
Diabetes (100)
Diagnostics (2181)
Digital health (12)
Diversity (1)
Diversity, equity & inclusion (13)
Drug discovery (48)
Drug pricing (15)
Drug shortages (2)
Duchenne muscular dystrophy (53)
Earnings (43865)
Editorial (5)
Employer branding (6)
Employer resources (32)
Events (39750)
Executive appointments (478)
FDA (4545)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (7)
Frontotemporal dementia (14)
Funding (396)
Gene editing (30)
Generative AI (7)
Gene therapy (120)
GLP-1 (157)
Government (437)
Guidances (203)
Healthcare (5088)
HIV (13)
Huntington's disease (6)
IgA nephropathy (16)
Immunology and inflammation (46)
Immuno-oncology (13)
Indications (35)
Infectious disease (352)
Inflammatory bowel disease (38)
Inflation Reduction Act (3)
Influenza (10)
Intellectual property (36)
Interviews (53)
IPO (7890)
IRA (3)
Job creations (1123)
Job search strategy (361)
JPM (4)
Kidney cancer (13)
Labor market (13)
Layoffs (110)
Leadership (6)
Legal (2338)
Liver cancer (22)
Longevity (3)
Lung cancer (126)
Lymphoma (83)
Machine learning (8)
Management (10)
Manufacturing (195)
MASH (59)
Medical device (3944)
Medtech (3972)
Mergers & acquisitions (7632)
Metabolic disorders (274)
mRNA (12)
Multiple sclerosis (21)
NASH (6)
Neurodegenerative disease (75)
Neuropsychiatric disorders (13)
Neuroscience (638)
NextGen: Class of 2026 (1675)
Non-profit (736)
Now hiring (7)
Obesity (108)
Opinion (33)
Ovarian cancer (42)
Pain (31)
Pancreatic cancer (56)
Parkinson's disease (69)
Partnered (6)
Patents (60)
Patient recruitment (130)
Peanut (6)
People (25542)
Pharmaceutical (7)
Pharmacy benefit managers (2)
Phase 1 (5094)
Phase 2 (7400)
Phase 3 (5896)
Pipeline (3178)
Policy (24)
Postmarket research (625)
Preclinical (1972)
Press Release (66)
Prostate cancer (69)
Psychedelics (3)
Radiopharmaceuticals (125)
Rare diseases (227)
Real estate (1889)
Recruiting (8)
Regulatory (5718)
Reports (18)
Research institute (309)
Resumes & cover letters (69)
Rett syndrome (25)
RNA editing (2)
RSV (2)
Schizophrenia (58)
Series A (65)
Series B (66)
Sickle cell disease (15)
Special edition (1)
Spinal muscular atrophy (36)
Sponsored (5)
Startups (1019)
Stomach cancer (1)
Supply chain (17)
Tariffs (7)
The Weekly (1)
Vaccines (97)
Venture capital (13)
Weight loss (39)
Women's health (8)
Worklife (1)
Date
Today (9)
Last 7 days (168)
Last 30 days (1064)
Last 365 days (8854)
2026 (3922)
2025 (9042)
2024 (11037)
2023 (13202)
2022 (18665)
2021 (19685)
2020 (18236)
2019 (13205)
2018 (10202)
2017 (10000)
2016 (9155)
2015 (12117)
2014 (9587)
2013 (7707)
2012 (8329)
2011 (8796)
2010 (8634)
Location
Africa (186)
Alabama (19)
Alaska (2)
Arizona (82)
Arkansas (2)
Asia (11901)
Australia (1721)
California (4247)
Canada (1303)
China (212)
Colorado (170)
Connecticut (204)
Delaware (82)
Europe (25975)
Florida (655)
Georgia (89)
Idaho (24)
Illinois (196)
India (26)
Indiana (136)
Iowa (9)
Japan (212)
Kansas (40)
Kentucky (19)
Louisiana (11)
Maine (57)
Maryland (414)
Massachusetts (3435)
Michigan (107)
Minnesota (224)
Mississippi (1)
Missouri (40)
Montana (18)
Nebraska (12)
Nevada (53)
New Hampshire (16)
New Jersey (1213)
New Mexico (5)
New York (963)
North Carolina (569)
North Dakota (5)
Northern California (2261)
Ohio (138)
Oklahoma (5)
Oregon (7)
Pennsylvania (733)
Puerto Rico (3)
Rhode Island (20)
South America (279)
South Carolina (19)
Southern California (1604)
Tennessee (74)
Texas (611)
United States (14826)
Utah (138)
Virginia (102)
Washington D.C. (17)
Washington State (367)
West Virginia (2)
Wisconsin (69)
Wyoming (1)
235,167 Results for "pepgen corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease
PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.
March 31, 2026
·
2 min read
·
Heather McKenzie
Press Releases
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 13, 2026
·
9 min read
Regulatory
PepGen’s Mid-Stage Myotonic Dystrophy Study Hit With ‘Surprise’ Pause
The timing of the partial hold is “odd,” according to analysts at Stifel, who noted that the preclinical data the FDA took issue with were filed in mid-2024.
March 5, 2026
·
2 min read
·
Tristan Manalac
Press Releases
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
March 5, 2026
·
13 min read
Press Releases
PepGen to Participate in the Leerink Global Healthcare Conference
March 3, 2026
·
1 min read
Press Releases
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
May 21, 2026
·
4 min read
Press Releases
PepGen Announces Regulatory Updates on FREEDOM2
March 5, 2026
·
6 min read
Press Releases
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 13, 2025
·
10 min read
Press Releases
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
December 9, 2025
·
2 min read
Press Releases
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
March 31, 2026
·
8 min read
1 of 23,517
Next
